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Cancers arising in mucosal tissues account for a
disproportionately large fraction of malignancies.
Immunoglobulin G (IgG) and the neonatal Fc receptor
for IgG (FcRn) have an important function in the
mucosal immune system that we have now shown
extends to the induction of CD8+ T cell-mediated
antitumor immunity. We demonstrate that FcRn
within dendritic cells (DCs) was critical for homeo-
static activation of mucosal CD8+ T cells that drove
protection against the development of colorectal
cancers and lung metastases. FcRn-mediated tumor
protection was driven by DCs activation of endoge-
nous tumor-reactive CD8+ T cells via the cross-pre-
sentation of IgG complexed antigens (IgG IC), as
well as the induction of cytotoxicity-promoting cyto-
kine secretion, particularly interleukin-12, both of
which were independently triggered by the FcRn–
IgG IC interaction in murine and human DCs. FcRn
thus has a primary role withinmucosal tissues in acti-
vating local immune responses that are critical for
priming efficient anti-tumor immunosurveillance.
INTRODUCTION
Cancers arising at mucosal barrier sites, particularly the lung,
large intestine (LI), stomach, and cervix, account for a consider-
able fraction of human malignancies (Siegel et al., 2012). One
contributing factor to the colon’s susceptibility to malignant
transformation is its immunosuppressive environment (MacDon-
ald et al., 2011), which is necessary for tolerance toward micro-
bial and dietary antigens but also results in dampened anti-can-Immcer immune responses (Revaz and Nardelli-Haefliger, 2005;
Saleh and Trinchieri, 2011). Identifying physiologic factors
capable of countering this inherent downside of local tolerance
is critical for understanding and manipulating carcinogenesis at
this, and possibly other, mucosal sites.
The production and handling of immunoglobulin G (IgG) are
critical components of mucosal immunity, particularly in the LI
where IgG accounts for a large fraction of homeostatic mucosal
immunoglobulin secretion (Kozlowski et al., 1997). The presence
of IgG in the intestinal lumen is associated with the actions of the
bidirectional IgG transport receptor, FcRn (neonatal Fc receptor
for IgG), which is expressed lifelong in most murine and human
endothelial, epithelial, and hematopoietic cells (Claypool et al.,
2004; Zhu et al., 2001). FcRn is uniquely capable of delivering
IgG into the lumen and also retrieving lumenal IgG and IgG con-
taining immune complexes (IgG IC), which are delivered into the
local immune system of the lamina propria (LP) (Claypool et al.,
2004; Yoshida et al., 2004). FcRn within antigen-presenting cells
such as dendritic cells (DCs) also plays a critical role in the pro-
cessing of antigens delivered as IgG IC and actively promotes
major histocompatibility complex (MHC) class I and class II
restricted T cell responses (Baker et al., 2011; Qiao et al.,
2008) that can alternatively promote anti-bacterial IgG-driven
colitis (Kobayashi et al., 2009) and protect from mucosal patho-
gens (Yoshida et al., 2006).
It is well accepted that cytotoxic CD8+ T cell-mediated
responses are critical for efficient anti-tumor immunity (Page`s
et al., 2005) and FcRn has recently been shown to enable
highly efficient cross-presentation of IgG-complexed antigens
by CD8CD11b+ DCs (Baker et al., 2011). Given the abundance
of both IgG and CD8CD11b+ monocyte-derived DCs in
mucosal tissues, especially in the context of malignancy
(Kozlowski et al., 1997; Ma et al., 2011; MacSween and East-
wood, 1980), we examined the role of FcRn in homeostatic
CD8+ T cell responses and as an effector of anti-cancer
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Figure 1. FcRn Protects against the Devel-
opment of Colorectal Cancer through a
Mechanism Independent of Intestinal
Microbiota
(A) Large intestine (LI) tumor incidence at 5months
of age and representative tumor histology in
ApcMin/+ and ApcMin/+Fcgrt/ mice. Scale bar
represents 100 mm.
(B) Tumor incidence in WT and Fcgrt/ litter-
mates treated with 8 doses of azoxymethane
(AOM).
(C) Tumor incidence in AOM/DSS-treated WT
and Fcgrt/ littermates.
(D) Tumor incidence and maximum tumor
diameter in WT and Fcgrt/ littermates in each
of four independent experiments with n R 3
mice per group per experiment.
(E) Percent survival of WT and Fcgrt/ litter-
mates treated with AOM/DSS. Significance was
assessed by log rank test.
(F) Richness indices of microbiota associated
with the distal LI of untreated 8-week-old WT
and Fcgrt/ littermates, as revealed by T-RFLP
analysis. n = 3–5 mice per group.
(G) Abundance of specific microbial species in the distal LI of untreated 7-week-old WT and Fcgrt/ littermates as assessed by qPCR. n = 9 mice per
group. Representative results of two (A, B, and E) or four (D) independent experiments each with n = 4–10 mice per group. All data represent mean ±
SEM. *p % 0.05, **p % 0.01, ***p % 0.005. See also Figure S1.
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FcRn Protects against the Development of Colorectal
Cancer
The majority of sporadic colorectal cancers (CRC) arise
following a defined series of mutational events often involving
inactivation of the adenomatous polyposis coli (APC) gene
(Walther et al., 2009). We thus began by investigating whether
FcRn could contribute to the development of CRC in ApcMin/+
mice, which possess an abnormal copy of Apc and spontane-
ously develop large numbers of small intestinal adenomas
(Saleh and Trinchieri, 2011). Typically, ApcMin/+ mice do not
develop colonic lesions in the absence of further insults,
such as the additional loss of a tumor suppressor gene (Aoki
et al., 2003; Saleh and Trinchieri, 2011). However, ApcMin/+
mice crossed with mice deficient in FcRn (Fcgrt/) spontane-
ously developed significantly more LI tumors than their
ApcMin/+ littermates (Figure 1A). Importantly, high grade
dysplasia and local invasion through the LP were detected
only in lesions from ApcMin/+Fcgrt/ but not ApcMin/+ animals
(Figure 1A; see Figure S1A available online). Of note, no differ-
ences were detected in the frequency of tumors in the small in-
testine (SI) (Figure S1B), where tumor development in ApcMin/+
mice does not depend on a second genetic event. We next
investigated the role of FcRn in the development of CRC
induced by the chronic exposure of a chemical carcinogen,
azoxymethane (AOM), which, upon repeated administration,
drives the development of colorectal malignancies (Meunier
et al., 2010). We observed that Fcgrt/ mice subjected to a
standard regimen of AOM administration developed signifi-
cantly more abundant and larger tumors (Figures 1B and
S1C) than did WT littermates. These data demonstrate the
importance of FcRn in determining susceptibility to the devel-
opment of sporadic CRC.1096 Immunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier InKnowing that inflammatory bowel disease is associated with
a heightened risk of CRC and that inflammation plays an impor-
tant role in driving even sporadic neoplasias (Coghill et al.,
2011; Herrinton et al., 2012), we examined whether FcRn-medi-
ated tumor protection extended to inflammation-associated
CRC. We found that Fcgrt/ mice treated with AOM and
dextran sodium sulfate (AOM/DSS) (Figure S1D) (Wirtz et al.,
2007) developed significantly larger and more abundant colo-
rectal adenocarcinomas than WT littermates (Figures 1C and
1D and S1E). Additionally, at higher concentrations of DSS,
Fcgrt/ mice experienced significantly poorer survival rates
compared to their WT littermates (Figure 1E), indicating that
FcRn-mediated anti-tumor immunity is potent enough to influ-
ence disease outcome. The smaller initial weight loss in the
Fcgrt/ mice compared to WT controls (Figure S1F) was
consistent with previous findings that Fcgrt/ mice are
protected from IgG-induced colitis (Kobayashi et al., 2009),
suggesting that tumor development in the context of FcRn-
deficiency is not simply due to increased inflammation.
Mounting evidence indicates that certain intestinal microbes
play a role in promoting the development of CRC (Arthur and
Jobin, 2011; Arthur et al., 2012). We thus profiled the intestinal
microbiota in our WT and Fcgrt/ littermate mice in order to
determine whether FcRn was exerting tumor protection through
the regulation of gut microbial composition. Terminal restriction
fragment length polymorphism (T-RFLP) analysis of the overall
microbial community composition and diversity from WT and
Fcgrt/ littermates revealed no significant differences in either
postweaning, eight-week-old mice or preweaning, two-week-
old mice (Figures 1F and S1G and S1H) in any of three separate
intestine-associated tissue compartments (proximal LI, distal
LI, and feces). However, regardless of genotype, the microbiota
were found to differ between these three tissue sites, thereby
confirming that our analysis had sufficient power to detectc.
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FcRn in DCs Drives Antitumor Immunosurveillancedifferences in microbial composition (Figures S1I and S1J). In
order to exclude differences in specific organisms previously
associated with CRC development (Arthur and Jobin, 2011),
we also assessed the abundance of these microbes in a sepa-
rate cohort of seven-week-old mice by using genus- or spe-
cies-specific qPCR and found no significant differences in either
the distal LI (Figure 1G) or feces (Figure S1K) of WT and Fcgrt/
littermates. Together, these data demonstrate that FcRn does
not protect against colorectal tumor development by regulating
intestinal microbial diversity or decreasing the presence of tu-
mor-promoting microbes.
FcRn Promotes the Retention and Activation of Tumor-
Protective CD8+ T Cells in the Large Intestine
In seeking to better understand the nature of FcRn-driven anti-
tumor immunity, we examined the immunological composition
of LP lymphocytes (LPL) in both dissected tumors and macro-
scopically tumor-free adjacent tissue. Although no differences
were noted in the numbers of CD4+ T cells, natural killer (NK)
cells, or macrophages (Figure S2A), significantly greater
numbers of CD8+ T cells were consistently found both within
tumor tissue and adjacent tissue of WT AOM/DSS-treated
mice in comparison to their Fcgrt/ littermates (Figures 2A
and 2B and S2B). This same deficiency in CD8+ T cell infiltration
into the tumor microenvironment of FcRn-deficient mice was
also seen in ApcMin/+Fcgrt/ animals in comparison to their
ApcMin/+ littermates (Figure S2C) as well as in Fcgrt/ mice
treated with AOM alone (Figure S2D). Furthermore, a greater
percentage of the CD8+ T cells from AOM/DSS-treated WT ani-
mals expressed intracellular granzyme B or surface lysosomal-
associated membrane protein-1 (LAMP1) (Figures 2A and 2B)
than did those from their Fcgrt/ littermates. We confirmed
the inefficient activation of CD8+ T cells in the context of FcRn-
deficiency by using anti-CD3 and anti-CD28 restimulation of
sorted effector CD8+CD44+CD62L T cells from the LI of AOM/
DSS-treated mice (Figure 2C). In response to this, CD8+ T cells
from Fcgrt/ tumor-bearing mice secreted only small amounts
of interferon-g (IFN-g), tumor necrosis factor (TNF), and inter-
leukin-10 (IL-10), the latter of which has recently been shown
to be critical for efficient cytotoxic CD8+ T cell-mediated anti-
viral and anti-tumor immunity (Mumm et al., 2011; Zhang and
Bevan, 2011). Although no differences were seen in the rates
of CD8+ T cell proliferation or apoptosis, as assessed by Ki-67
and annexin V staining, respectively (Figure S2E), both upregula-
tion of CD103, an integrin associated with intestinal T cell reten-
tion (Le Floc’h et al., 2007), and increased expression of activa-
tion-associated CD44 on CD62L+CD8+ T cells were observed in
CD8+ T cells infiltrating the LP of WT but not Fcgrt/ littermates
(Figure S2F). This was specific for the tumor-associated tissues
because these differences were not observed in the mesenteric
lymph nodes (MLN) (Figure S2F) and is notable because the
presence of high numbers of CD8+CD44+CD62L+ cells bearing
an effector memory T (Tem) cell phenotype has been associated
with improved prognosis in human CRC patients (Page`s et al.,
2005). These data are thus most consistent with a role for
FcRn in driving anti-tumor immunity by promoting the retention
and activation of cytotoxic T cells having homed to the LI.
We next sought to confirm that FcRn-mediated activation of
CD8+ T cells was critical for its tumor protective function by usingImmadoptive transfer of CD8+ T cells isolated from both theMLN and
LP of AOM/DSS-treated donors in order to minimize the number
of T cells likely to have been exposed to a tolerizing tumor micro-
environment (Chen and Mellman, 2013). Transfer of CD8+ T cells
from WT donors, but not from Fcgrt/ donors, into Fcgrt/ re-
cipients decreased tumor frequency and total neoplastic colon
surface area (tumor load) (Grivennikov et al., 2012) to quantities
similar to those observed in WT mice and significantly less than
seen in PBS treated Fcgrt/ animals (Figure 2D). Similar exper-
iments performed with adoptively transferred CD4+ T cells
revealed that CD4+ T cells are not sufficient for FcRn-mediated
tumor protection (Figure S2G). Rather, our data are consistent
with activation of cytotoxic CD8+ T cells being a primary mecha-
nismbywhich FcRn-driven tumor immune surveillance operates.
FcRn-Dependent Cross-Priming by Dendritic Cells
Induces Effective Anti-Tumor CD8+ T Cell Responses
In light of our recent demonstration that FcRn in CD8CD11b+
DCs, in which the acidic endosomal and phagosomal pH favors
FcRn–IgG binding, drives the cross-presentation of IgG IC-deliv-
ered antigens and the resulting activation of CD8+ T cells (Baker
et al., 2011), we sought to determine whether FcRn-dependent
cross-priming by DCs was required for its anti-tumor effects.
Given that this mechanism would necessitate the presence of
tumor-reactive IgG to form IC and that tumor-reactive IgG has
previously been documented in human CRC (Auer et al., 1988;
Kijanka et al., 2010), we first confirmed the presence of these
effector molecules in our model. Both ELISA (Figures 3A and
S3A) and immunoblotting (Figure S3B) assays with IgG-depleted
tumor epithelium lysates from AOM/DSS-treated mice as the
source of antigen verified that tumor-reactive IgG was present
in the serum and in MLN and LI tissue homogenates of AOM/
DSS-treated WT and Fcgrt/ littermates but not non-tumor-
bearing controls. We also noted increases of similar magnitude
in anti-phosphatidylserine and anti-cardiolipin IgG, which have
been shown to promote the formation of IC-containing apoptotic
bodies or mitochondria released by dying tumor cells (Kepp
et al., 2009), in the serum of both WT and Fcgrt/ littermates
(Figure S3C). Moreover, both tumor-reactive IgG (Figures 3A
and S3A) and total IgG (Figure S3D) were also present in similar
quantities in the MLN and intestinal tissues of AOM/DSS-treated
WT and Fcgrt/ mice. Thus, although FcRn is critically impor-
tant in protecting circulating IgG from catabolism and our
Fcgrt/mice were predictably systemically hypogammaglobu-
linemic (Figure S3D) (Roopenian et al., 2003), this was not the
case in tissues for either total IgG (Figure S3D) or tumor-specific
IgG (Figure 3A) where local IgG production by resident plasma
cells is likely sufficient to normalize tissue IgG quantities. Thus,
the extreme susceptibility of Fcgrt/ mice to tumor develop-
ment cannot simply be attributed to a local deficiency in the
IgG ligand for FcRn.
Havingconfirmed the presenceof IgGcapable of binding tumor
antigens in bothWTandFcgrt/mice,weverified that therewere
no differences in the distribution of DCs subsets or DCs FcgR
expression in theLILPofWTandFcgrt/ littermates (FigureS3E).
Thiswasparticularly important given that FcRn-dependent cross-
presentation requires FcgR for the initial IgG IC internalization
(Baker et al., 2011). Evaluation of the functional characteristics
of sorted CD8CD11b+ and CD8+CD11b DCs from the MLN,unity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inc. 1097
Figure 2. FcRn Drives the Activation and Retention of Tumor-Reactive Cytotoxic CD8+ T Cells, which Confer Tumor Protection
(A) Frequency of CD8+ T cells in the lamina propria lymphocyte (LPL) fraction of tumor and adjacent LI tissue in WT and Fcgrt/ littermates (upper panels)
following AOM/DSS treatment. Cytotoxic potential of cells within the CD3+CD8+ gate was assessed by intracellular staining for granzyme B (middle panels) or
surface staining of LAMP1 (lower panels).
(B) Mean CD8+ T cell frequency and cytotoxic potential in WT and Fcgrt/ mice, as assessed by flow cytometry, in each of three independent experiments.
(C) Cytokine secretion of sorted effector CD8+ CD44+CD62L cells from the LP of tumor and adjacent tissue of AOM/DSS treatedWT and Fcgrt/mice following
24 hr restimulation with anti-CD3 and anti-CD28.
(D) Tumor incidence and tumor load (sum of the diameters of all tumors) in recipient mice adoptively transferred with CD8+ T cells fromWT or Fcgrt/ AOM/DSS-
treated donors. Significance was assessed by Mann-Whitney test. Representative results of three independent experiments with n R 4 mice per group per
experiment. All data represent mean ± SEM. Abbreviations are as follows: NS, not significant; ND, not detected. *p% 0.05, **p% 0.01, ***p% 0.005. See also
Figure S2.
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thatDCs fromFcgrt/micewere significantly deficient in thepro-
duction of cytokines (IFN-g, IL-12) and transcription factors
(T-bet) known to drive effective cytotoxic T cell-mediated immu-
nity (Figure 3B) (Garrett et al., 2009; Gerosa et al., 1996; Trinchieri,
2003; Zhang and Bevan, 2011). These differences were greatest1098 Immunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inin the CD8CD11b+ DCs subset, which is highly efficient at
FcRn-dependent cross-presentation (Baker et al., 2011). Further-
more, analysis of whole-tissue transcripts taken from the tumor
and adjacent tissue of tumor-bearing mice (Figures S3F–S3H)
clearly demonstrated decreased transcripts at the tissue level of
these procytotoxicity cytokines in FcRn-deficient animals. Thesec.
Figure 3. CD8–CD11b+ DCs Utilize FcRn to Efficiently Prime Protective Anti-tumor CD8+ T Cell Responses
(A) Tumor antigen-specific IgG in the serum or MLN and LI homogenates of AOM/DSS treated WT or Fcgrt/mice. ELISA plates coated with lysates from tumor
epithelium were probed with dilutions of serum or tissue homogenates from tumor bearing mice.
(B) Transcript profiles of sorted CD8CD11b+ and CD8+CD11b DCs subsets isolated from the indicated tissue compartment of AOM/DSS-treated WT and
Fcgrt/ littermates.
(C) Tumor incidence and survival in Fcgrt/ recipients adoptively transferred with DCs from the MLN and LP of AOM/DSS-treated WT or Fcgrt/ donors.
Endpoint survival was assessed with a chi-square test.
(D) CD8+ T cell frequency in the LI LP following transfer of WT DCs to AOM/DSS-treated Fcgrt/ recipients.
(E) Tumor incidence (upper panel) and LI LP CD8+ T cell frequency (lower panels) in ItgaxcreFcgrtFl/Fl mice and their littermate FcgrtFl/Fl controls upon treatment
with AOM/DSS.
(F and G) Tumor incidence (F) and survival (G) of CD8+ T cell-depleted Fcgrt/mice adoptively transferred with WT DCs. CD8+ T cells were depleted by chronic
i.p. administration of anti-CD8 antibody (or isotype control). Representative results of three (B–E) or two (A and F) independent experiments with n = 3–6mice per
group per experiment. All data represent mean ± SEM. NS, not significant. *p% 0.05, **p% 0.01, ***p% 0.005. See also Figure S3.
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FcRn in DCs Drives Antitumor Immunosurveillancedata thus indicate that FcRn within DCs is required for the estab-
lishment of a tissue level cytokine environmentwithin the LI that is
conducive to effective CD8+ T cell activation.ImmIn order to demonstrate that FcRn-sufficient DCs were directly
involved in driving anti-tumor immunity, we first conducted a
series of adoptive transfer experiments. Fcgrt/mice receivingunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inc. 1099
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FcRn in DCs Drives Antitumor ImmunosurveillanceCD8CD11b+ DCs (Figure S3I) from AOM/DSS-treated WT do-
nors developed significantly fewer tumors than control PBS-
treated Fcgrt/ mice or Fcgrt/mice given Fcgrt/ DCs (Fig-
ure 3C) despite equivalent homing and persistence of donor DCs
from donors of both genotypes (Figure S3J). Furthermore,
administration of WT DCs, but not Fcgrt/ DCs, protected
Fcgrt/ recipients from AOM/DSS-induced mortality (Fig-
ure 3C). Of considerable interest, the transfer of even a small
number of FcRn-sufficient WT CD8CD11b+ DCs was able to
normalize the infiltration of CD8+ T cells into adjacent and tumor
LI tissue of Fcgrt/mice (Figure 3D), thereby confirming that no
primary defect in CD8+ T cells is operating in Fcgrt/ mice.
Ex vivo assays on DCs isolated from the MLN of Fcgrt/ recip-
ients 7 days after the transfer of WT DCs further confirmed that
FcRn-dependent cross-priming capacity had been restored
(Figure S3K). We next validated these findings by using mice
bearing a floxed Fcgrt gene (FcgrtFl/Fl) (Montoyo et al., 2009),
which were bred with Itgaxcre animals in order to specifically
delete FcRn in DCs (Figure S3L). Treatment of ItgaxcreFcgrtFl/Fl
mice with AOM/DSS induced significantly more colorectal tu-
mors than were found in their FcgrtFl/Fl littermates (Figure 3E).
Of note, ItgaxcreFcgrtFl/Fl mice were also deficient in infiltration
of the LI LPwith CD8+ T cells (Figure 3E), thereby further support-
ing our hypothesis that FcRn specifically within DCs orchestrate
CD8+ T cell activation within the intestine. We confirmed this by
performing simultaneous DCs transfer and CD8+ T cell depletion
experiments, which revealed that removal of CD8+ T cells from
Fcgrt/ recipients of WT CD8CD11b+ DCs undergoing AOM/
DSS treatment abrogated the improvement in tumor incidence
and cancer survival conferred by the WT DCs (Figures 3F and
3G). These data thus confirm that an important mechanism of
FcRn-mediated tumor protection is DCs-dependent activation
of CD8+ T cells via cross-priming and conditioning of the cyto-
kine environment.
FcRn within DCs Enables Activation of Endogenous
CD8+ T Cells toward Defined Cognate Tumor Antigens
The limitations of our CRCmodels to examine antigen specificity
led us to seek an alternative approach in order to investigate the
link between tumor-antigen-specific IgG and CD8+ T cell re-
sponses. We turned to a pulmonary metastasis model by using
a melanoma cell line (B16) expressing the OVA antigen (OVA-
B16) (Falo et al., 1995). Knowing that FcRn is highly expressed
in the lung (Spiekermann et al., 2002), we first verified that the
lungs of WT mice were enriched in CD8+ T cells in comparison
to those of their Fcgrt/ littermates (Figure S4A). These data
extend the range of FcRn-regulated mucosal CD8+ T cell re-
sponses to a second site that is frequently affected by cancer
(Siegel et al., 2012) and is known to engage in both FcRn-depen-
dent immune responses (Yoshida et al., 2004) and immunolog-
ical crosstalk with the intestine (Keely et al., 2012). Subsequent
to intravenous (i.v.) administration of OVA-B16, we observed a
rise in anti-OVA IgG in lung homogenates and serum from both
WT and Fcgrt/ littermates (Figures S4B and S4C). This is
consistent with our findings of equivalent numbers of anti-OVA
IgG-secreting B cells in the LN and spleens of WT and Fcgrt/
mice (Figure S4D) and confirms that there is no defect in the local
production of tumor antigen-specific IgG in FcRn deficient
animals. As expected, WT mice developed considerably fewer1100 Immunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inpulmonary nodules than Fcgrt/mice and subcutaneous vacci-
nation at a distant site with WT DCs, but not Fcgrt/ DCs,
conferred protection from pulmonary metastatic seeding to
Fcgrt/ recipients (Figure 4A). By using SIINFEKL/H-2kb
tetramer staining, we established that a greater proportion of
endogenous CD8+ T cells with OVA tumor-antigen specificity
arose in the lungs of WT mice receiving OVA-B16 tumor cells
than in their Fcgrt/ littermates (Figure 4B). In order to confirm
that DCs-based, FcRn-mediated tumor protection was depen-
dent upon activation of CD8+ T cells, we chronically adminis-
tered a depleting anti-CD8 antibody to Fcgrt/ recipients
immunized with WT CD8CD11b+ DCs and given OVA-B16.
Whereas the transfer of WT DCs significantly decreased the inci-
dence of metastatic pulmonary nodules in Fcgrt/ recipients,
this protection was abrogated by depletion of CD8+ T cells (Fig-
ure 4C). We further demonstrated that the main locus of FcRn-
mediated tumor immunosurveillance was the DCs by showing
that ItgaxcreFcgrtFl/Flmice developed greater numbers of pulmo-
nary nodules than did their FcgrtFl/Fl littermates and were less
efficient in driving the expansion of tumor-specific CD8+ T cells
(Figure 4D). These findings identify both endogenously arising
tumor-reactive IgG and cognate endogenously derived CD8+
T cells as important components of the mechanism by which
DCs exert FcRn-dependent tumor immune surveillance.
We next sought to demonstrate that targeting FcRn-mediated
cross-presentation with a single IgG-complexed tumor antigen
could be a viable and attractive strategy for anti-tumor immuno-
therapy. In order to do so, we made use of a non-FcRn binding
IHH-IgG, which contains three point mutations in the Fc domain
that disable FcRn, but not Fcg receptor, binding (Baker et al.,
2011) and an enhanced FcRn binding LS-IgG, which contains
the ‘LS’ mutation (M428L/N434S) known to increase FcRn bind-
ing while maintaining pH dependency (Claypool et al., 2004;
Zalevsky et al., 2010). When OVA-reactive OT-I CD8+ T cells
were stimulated ex vivo by WT DCs primed with OVA-containing
IgG or IHH-IgG IC and adoptively transferred to Fcgrt/ recip-
ient mice, only CD8+ T cells primed by IgG IC-pulsed DCs pro-
tected against the development of pulmonary metastases (Fig-
ure 4E). Furthermore, immunizing mice with DCs loaded with
OVA-containing LS-IgG IC conferred significantly greater pro-
tection from metastasis development than did immunization
with IgG IC-loaded DCs (Figure 4F). This is consistent with our
finding that LS-IgG IC was more potent than native IgG IC at
inducing cross-priming of low-dose antigen in vitro (Figure S4E).
Collectively, these data demonstrate that targeting the immu-
nostimulatory potential of FcRn with complexes formed from a
single defined tumor antigen and IgG or FcRn-binding-enhanced
IgG is a tractable and effective anti-tumor therapeutic approach.
Dendritic Cell FcRn Enables Homeostatic CD8+ T Cell
Activation and Tc1 Cytokine Secretion in the LI
Our discovery that FcRn-mediated anti-tumor immunity in the LI
occurs in the absence of preexisting inflammation suggested
that FcRn might be playing an active role in intestinal immuno-
surveillance before the onset of cancer development. We thus
investigated whether FcRn regulates CD8+ T cell activation in
the LI under homeostatic conditions. Similar to our observation
in AOM/DSS-treated mice, and despite the well-known differ-
ences in circulating IgG concentrations (Roopenian et al.,c.
Figure 4. FcRn Drives the Induction of
Endogenous Tumor-Reactive CD8+ T Cells
and Can Be Therapeutically Targeted
(A) Incidence of pulmonary metastatic nodules
formed by i.v. administered OVA-expressing B16
melanoma cells (OVA-B16) in WT or Fcgrt/
mice or Fcgrt/ mice preimmunized with WT or
Fcgrt/ DCs.
(B) Frequency of endogenously occurring OVA-
specific CD8+ T cells in WT and Fcgrt/ metas-
tasis-bearing mice. Left panel demonstrates
results from individual animals in a single experi-
ment. Right panel shows the results of three in-
dependent experiments each with n = 3–6 mice
per group.
(C) Frequency of pulmonarymetastases frommice
treated as in (A) and given either a CD8+ T cell-
depleting antibody or isotype control.
(D) Frequency of pulmonary metastatic nodules
and OVA-specific CD8+ T cells in the lungs of
FcgrtFl/Fl and ItgaxcreFcgrtFl/Fl littermates.
(E) Incidence of pulmonary metastatic nodules in
WT or Fcgrt/ mice or Fcgrt/ mice adoptively
transferred with OVA-specific CD8+ T cells
primed ex vivo by DCs loaded with OVA-con-
taining IgG IC, FcRn non-binding IHH-IgG IC, or
soluble OVA.
(F) Incidence of pulmonary nodules in OVA-B16-
treated WT and Fcgrt/ mice preimmunized with
WT DCs loaded ex vivo with OVA-containing IC
formed with IgG or enhanced FcRn-binding
LS-IgG. Representative results of three (A, B, and D) or two (C, E, and F) independent experiments with n = 3–6 mice per group per experiment. All data
represent mean ± SEM. NS, not significant. (*) p = 0.09, *p % 0.05, **p % 0.01, ***p % 0.005. See also Figure S4.
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FcRn in DCs Drives Antitumor Immunosurveillance2003), similar quantities of IgG were present in the LI and MLN
tissue of both WT and Fcgrt/ littermates under steady-state
conditions (Figure 5A). These results confirmed that the suscep-
tibility of Fcgrt/ mice to tumor development could not be
attributed to homeostatic local IgG deficiency. In spite of these
comparable tissue IgG amounts, however, the LI LP of WT
mice contained greater quantities of CD8+ T cells, but not other
lymphocyte subsets, relative to that observed in Fcgrt/ mice
(Figure 5B). A similar deficiency in CD8+ T cell infiltration into
the LI LP was present in untreated ItgaxcreFcgrtFl/Fl mice
compared to their littermate controls (Figure 5C). Moreover,
CD8+ T cells from the LI LP of WT mice not only secreted more
IFN-g, IL-10, and TNF upon restimulation in comparison to
T cells obtained from Fcgrt/ littermates (Figure 5D) but also ex-
pressed more activation and cytotoxicity-associated cytokines
when assessed immediately after isolation (Figure 5E). Adoptive
transfer of congenic CD8+ T cells intoWT and Fcgrt/ recipients
indicated that not only did a greater number of transferred T cells
accumulate in the LI LP ofWTmice 10 days after transfer but also
these upregulated significantly more of the activation marker
CD44 (Figure S5A), consistent with our findings of deficient
CD8+CD44+CD62L+ T cells in Fcgrt/ tumor-bearing mice (Fig-
ure S2F). In contrast, CD8+ T cells from WT or Fcgrt/ donors
transferred to congenic WT recipients homed equally well to
the LI LP (Figure S5B), thereby confirming that the effect of
FcRn is within the local tissue microenvironment rather than be-
ing intrinsic to the T cells.
Given that efficient CD8+ T cell activation requires an appro-
priate cytokine environment, we next examined the local tissueImmcytokine milieu of Fcgrt/ mice under homeostatic conditions.
Tissueexplant cultures (Figure5F) andanalysisof tissueRNA tran-
scripts (Figure S5C) indicated that in the absence of FcRn, the
MLN and LI were deficient in their ability to produce cytotox-
icity-promoting IL-12 and TNF. By examining the cytokine profiles
of sorted DCs from the MLN of untreated WT and Fcgrt/ litter-
mates,weobservedasimilardependence for FcRnon theexpres-
sion of IFN-g, IL-12p35, T-bet, and TNF, but not IL-23p19, in
CD8CD11b+ DCs (Figure 5G). This suggests that FcRn within
the CD8CD11b+ subset of tissue-associated DCs is responsible
for establishing a cytokine milieu conducive to CD8+ T cell activa-
tion and of thus promoting tumor immunosurveillance in the LI.
Similarly, CD4+ T cells from the LI of untreated Fcgrt/ mice
were deficient in secretion of Th1 cell-associated cytokines
uponanti-CD3and anti-CD28 restimulationdespite being present
in equal amounts inWTandFcgrt/mice (Figures S5D andS5E).
These data suggest that IgG IC ligation of FcRn in DCs contrib-
utes to the establishment of homeostatic Th1 and T cytotoxic-1
(Tc1) cell polarization and CD8+ T cell function in the LI.
Multimeric IgG IC Ligation of FcRn in DCs Induces
the Production of IL-12
Knowing that IL-12 is a potent enhancer of CD8+ T cell-mediated
immunity (Gerosa et al., 1996; Trinchieri, 2003) and having
consistently observed greater quantities of IL-12 in DCs, partic-
ularly the CD8CD11b+ subset, from the mucosal tissues of WT
compared to Fcgrt/ littermates, we next investigated the
effects of ligation of FcRn by IgG IC or FcRn non-binding IHH-
IgG IC on IL-12 secretion. Incubation of WT CD8CD11b+ DCsunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inc. 1101
Figure 5. FcRn within DCs Enables Homeostatic CD8+ T Cell Activation and IL-12 Production in the LI
(A) IgG isotype content of the serum and LI or MLN homogenates in untreated WT and Fcgrt/ littermates.
(B) CD8+ T cell frequency of the LI LPL fraction of untreated WT and Fcgrt/ littermates in a single experiment (left panels) or across three independent
experimental repeats (right panel).
(C) Frequency of CD8+ T cells in the LPL fraction of FcgrtFl/Fl and ItgaxcreFcgrtFl/Fl littermates.
(D) Cytokine secretion by CD8+ T cells sorted from LI LP of untreated WT and Fcgrt/ mice following 24 hr restimulation with anti-CD3 and anti-CD28.
(E) Transcript profiles of CD8+ T cells sorted from LI LP of untreated littermate control mice.
(F) Cytokine secretion from 24 hr tissue explant cultures of the MLN and LI of untreated WT and Fcgrt/ mice.
(G) Transcript profiles of sorted CD8CD11b+ DCs from the MLN of untreated littermates. Representative results of three independent experiments with n = 3–5
mice per group per experiment. All data represent mean ± SEM. NS, not significant. *p% 0.05, **p% 0.01, ***p% 0.005. See also Figure S5.
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FcRn in DCs Drives Antitumor Immunosurveillancefrom the MLN and spleen of untreated WT mice with FcRn bind-
ing IgG IC, but not IHH-IgG IC, led to the direct induction of IL-
12p35 transcripts (Figure 6A). Similarly, IgG IC stimulation of
WT but not Fcgrt/ CD8CD11b+ DCs isolated from the MLN
of AOM/DSS treated mice resulted in increased IL-12 secretion
(Figure 6B). Mechanistically, we observed that stimulation of
Fcgrt/ DCs with IgG IC led to considerably less phosphoryla-
tion of the Th1 cell-associated transcription factor STAT-1
(Antonios et al., 2010) than was seen in WT DCs (Figure 6C).
We confirmed that STAT-1 activation was an important compo-
nent of FcRn-induced IL-12 production by treating CD8CD11b+
DCs isolated from Stat1/ mice with IgG IC or IHH-IgG IC and
observed that, as for IHH-IgG IC, IgG IC failed to induce IL-
12p35 in the absence of STAT-1 (Figure 6D). We further showed
that stimulation of WT CD8CD11b+ DCs with IgG IC led to
significantly greater nuclear translocation and IL-12p35 pro-
moter binding of both interferon regulatory factor-1 (IRF-1) and
NF-kB p65 than was observed in Fcgrt/ DCs or upon stimula-
tion with IHH-IgG IC (Figures 6C,E) and confirmed that this was
MYD88 independent (Figures S6A and S6B). IgG IC ligation of
FcRn in DCs is thus able to directly induce the production of
the potent Th1 and Tc1 cell-associated cytokine IL-12.
In order to demonstrate that FcRn-mediated induction of IL-
12 by DCs contributes to the ability of this receptor to promote
anti-tumor immune surveillance, we next performed IL-121102 Immunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inneutralization experiments in which Fcgrt/ mice adoptively
transferred with WT DCs were subjected to AOM/DSS treat-
ment in the presence of a neutralizing anti-IL-12 antibody or
isotype control (Wysocka et al., 1995). Whereas WT DCs
were able to decrease the incidence of colorectal tumors in
Fcgrt/ recipients down to the numbers seen for WT control
mice, this protection was completely abrogated when mice
were treated with anti-IL-12 (Figure 6F). However, in vitro
coculture assays demonstrated that FcRn-dependent CD8+
T cell priming was independent of IL-12 production
(Figure S6C), indicating that the cross-presenting and cyto-
kine-inducing functions of FcRn are independent. Collectively,
these data indicate that FcRn-driven DCs-mediated tumor pro-
tection results from a dual ability to promote cross-presentation
of IgG IC-delivered antigen to CD8+ T cells, as well as to induce
secretion of IL-12, which, notably, can augment the cytotoxic
capacity of T cells once primed.
FcRn Expressing DCs Predict Survival in Human CRC
and Secrete FcRn-Dependent IL-12
To examine whether our observations in mice were relevant to
the development of human CRC, we evaluated the presence of
FcRn-expressing DCs in 50 matched cases of human CRC and
adjacent normal tissue utilizing immunohistochemical staining
for FcRn and CD11c. As shown in Figures 7A and S7A,c.
Figure 6. IgG IC Ligation of FcRn in
CD8–CD11b+ DCs Induced IL-12 Production
via Activation of a Signaling Cascade
(A) Induction of IL-12p35 upon ex vivo stimulation
of WT CD8CD11b+ DCs from the spleen or MLN
with IgG IC or FcRn nonbinding IHH-IgG IC for 6 hr.
(B) IL-12 secretion after 24 hr IgG IC stimulation of
CD8CD11b+ and CD8+CD11b DCs sorted from
the MLN of AOM/DSS-treated WT and Fcgrt/
mice.
(C) Phosphorylation of STAT-1 and nuclear trans-
location of IRF-1 and NF-kB p65 upon IgG IC
stimulation of DCs isolated from WT or Fcgrt/
mice.
(D) IL-12 transcript production by WT or Stat-1/
CD8CD11b+ DCs following stimulation with IgG
or IHH-IgG IC for 6 hr.
(E) Binding of IRF-1 and NF-kB p65 to the pro-
moters of IL-12p35 and IL-12p40 upon stimulation
of WT or Fcgrt/ DCs with IgG IC or IHH-IgG IC
for 4 hr.
(F) Tumor incidence in mice adoptively transferred
with WT DCs and treated with a neutralizing
anti-IL-12 antibody or isotype control. Represen-
tative results of three (A–E) or one (F) independent
experiments with n = 3–7 mice per group per
experiment. All data represent mean ± SEM.
*p % 0.05, **p % 0.01, ***p % 0.005. See also
Figure S6.
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FcRn in DCs Drives Antitumor ImmunosurveillanceFcRn+CD11c+ cells were clearly present in the stroma of both
tumor LI (upper panels) and adjacent normal LI (lower panels)
of CRC patients. Furthermore, a direct interaction of FcRn+
stromal cells with CD8+ T cells was observed in both tumor
LI (upper panels) and CRC-adjacent normal LI (lower panels)
(Figures 7B and S7B). Importantly, the frequency of FcRn+
CD11c+ DCs correlated positively with the presence of CD8+
T cells in the CRC-adjacent normal stroma (Figure S7C). In or-
der to determine whether the presence of FcRn+CD11c+ cells in
the tumor microenvironment had an impact on patient survival,
we stained a well-characterized tissue microarray of 183 hu-
man CRC cases for these cells and analyzed their impact on
disease outcome (Karamitopoulou et al., 2011). Kaplan-Meier
survival curves indicated that patients with R10 FcRn+CD11c+
cells per punch had significantly longer survival times over a
70 month follow-up than did those with <10 FcRn+CD11c+
cells (Figure 7C). Furthermore, increasing numbers of FcRn+-
CD11c+ cells were found to have a positive effect on patient
survival in univariate proportional hazard analysis (p =
0.0333), an effect that was maintained in a multivariable anal-
ysis (p = 0.0388) when adjusting for the indicated clinical pa-
rameters (Figure S7D). Collectively, these studies demonstrate
that FcRn-expressing DCs localize to both the CRC and CRC-
associated adjacent microenvironment, correlate with the infil-
tration of CD8+ T cells into the tumor tissue, and predict
improved prognosis for CRC patients.
In order to demonstrate a direct causative link between hu-
man FcRn and anti-tumor immunosurveillance, we generated
chimeric mice in which irradiated Fcgrt/ recipients were re-
constituted with bone marrow from donors that were eitherImmWT, Fcgrt/ or expressed human FcRn and b2-microglobulin
(b2M) on an Fcgrt/ background (hFCGRT-hB2M-mFcgrt/)
and thus possess only the human form of the receptor
(Roopenian et al., 2003). When the chimeras were subjected
to AOM/DSS treatment, Fcgrt/ mice reconstituted with
Fcgrt/ bone marrow developed far greater numbers of colo-
rectal tumors than did Fcgrt/ mice reconstituted with either
WT or hFCGRT-hB2M-mFcgrt/ bone marrow (Figure 7D).
Furthermore, CD8+ T cell infiltration in the LI LP of tumor-
bearing mice was restored to WT amounts in Fcgrt/ mice
possessing human-FcRn expressing hematopoietic cells
(Figure S7E). Thus, human FcRn is equally as capable of
orchestrating anti-tumor immunosurveillance as is its murine
ortholog.
We lastly sought to confirm that the intracellular mecha-
nisms we had demonstrated in mouse DCs were also opera-
tive in their human equivalents by using human monocyte-
derived DCs (hMoDCs), which are phenotypically akin to the
murine CD8CD11b+ DCs subset which engage in efficient
FcRn-dependent cross-priming (Figures S7F and S7G) (Baker
et al., 2011; Collin et al., 2011). As shown in Figure 7E, stimu-
lation of hMoDCs by IgG IC led to greater production of
both IL-12p35 and IL-12p40 than stimulation with non-FcRn-
binding IHH-IgG IC. Furthermore, IgG IC induced greater
phosphorylation of STAT-1 and nuclear translocation of IRF-1
after both 1 hr and 3 hr than did IHH-IgG IC (Figures 7F and
S7H). Together, these data support the importance of human
FcRn function in DCs in enabling anti-tumor immunity through
its ability to regulate IL-12 production and CD8+ T cell
activation.unity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inc. 1103
Figure 7. FcRn Expressing DCs Predict Sur-
vival in Human CRC and Secrete IL-12 upon
FcRn Stimulation
(A) Double immunohistochemical staining of
FcRn+CD11c+ DCs in the stroma of CRC (upper
panels) and CRC-adjacent normal LI (lower
panels). FcRn is brown, CD11c is red. Scale bar
left panels represents 100 mm. Scale bar right
panels represents 20 mm.
(B) Colocalization of FcRn+ DCs (brown) and CD8+
T cells (red) in stroma of CRC (upper panels) and
CRC-adjacent normal LI (lower panels). Arrow-
heads indicate areas of colocalization.
(C) Kaplan-Meier survival curves of 183 patients
with high (R10 per core) and low (<10 per core)
tumor infiltration by CD11c+FcRn+ cells.
(D) Incidence of tumors in chimeric mice treated
with AOM/DSS. WT recipients were reconstituted
with WT bone marrow. Fcgrt/ recipients were
reconstituted with Fcgrt/, WT, or hFCGRT-
hB2M-mFcgrt/ bone marrow. Representative
result of two independent experiments with n =
4–5 mice per group per experiment.
(E) hIL-12p35 and hIL-12p40 transcript expression
in hMoDCs upon stimulation with FcRn-binding
(IgG IC) or FcRn nonbinding (IHH-IgG IC) immune
complexes.
(F) Nuclear translocation of IRF-1 and phosphor-
ylation of STAT-1 in hMoDCs upon stimulation
with IgG IC or IHH-IgG IC. Data in (A) and (B) are
representative of a total of 50 matched CRC and
adjacent normal LI pairs. Data in (E) and (F) are
representative of six donors processed in pairs in
each of three independent experiments. All data
represent mean ± SEM. *p % 0.05, **p % 0.01,
***p% 0.005. See also Figure S7.
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The findings presented here identify a key physiological role for
FcRn-mediated cross-priming in driving homeostatic activation
of CD8+ T cells and in CD8+ T cell-mediated anti-tumor immune
surveillance in the LI and lung. We have clearly established in
multiple tumor models that genetic deletion of FcRn increases
susceptibility to carcinogenesis at these mucosal sites. Transfer
of CD8+ T cells primed under FcRn-sufficient conditions or of WT
FcRn-bearing DCs was capable of rescuing FcRn-deficient ani-
mals from both a high tumor burden and tumor-induced mortal-
ity. This depended upon IgG IC-mediated ligation of FcRn within
mucosal DCs which enabled the priming of tumor antigen-spe-
cific endogenous CD8+ T cells via its dual induction of antigen
cross-presentation and the production of immune-enhancing
cytokines such as IL-12. We have also confirmed the human
relevance of our findings by demonstrating that FcRn-express-
ing humanDCs respond to IgG IC stimulation with the production
of IL-12, that FcRn+ DCs localize to the CRC microenvironment
where their ability to induce anti-tumor immunity contributes to
improved patient survival, and that human FcRn in hematopoiet-
ic cells can substitute for itsmouse ortholog in protecting against
the development of CRC. Our findings are furthermore consis-
tent with a model in which IgG IC binding to FcRn within mucosal
DCs directs not only the intracellular trafficking of IgG IC but also
the previously unrecognized organization of a signaling cascade,1104 Immunity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inwhich enhances the secretion of cytotoxicity-promoting cyto-
kines. These features of FcRn biology uniquely enable potent
anti-tumor immunosurveillance, which requires only small
amounts of antigen and is capable of overcoming the immuno-
regulatory environment characteristic of intestinal and, poten-
tially, other mucosal tissues (MacDonald et al., 2011). Moreover,
our demonstration that FcRn-deficiency does not result in
decreased quantities of tissue-associated IgG but rather dimin-
ished numbers and function of CD8+ T cell under homeostatic
conditions further suggests that a major function of FcRn in
tissues is in the regulation of cell mediated immunity rather
than the protection of IgG from catabolism which is observed
systemically.
An important prerequisite for FcRn-mediated tumor protection
is the presence of IgG capable of recognizing a tumor antigen
and initiating a cascade of FcRn-dependent anti-tumor re-
sponses that will feed in to the recently described ‘‘Cancer-Im-
munity Cycle’’ (Brichory et al., 2001; Chen and Mellman, 2013;
Desmetz et al., 2011). The presence of appreciable quantities
of endogenous IgG autoantibodies reactive or cross-reactive to-
ward altered or abnormally expressed tumor antigens is well
documented, and these are likely to serve as the initiators for
FcRn-mediated tumor protection. Specifically, the accelerated
release of tumor-associated antigens, either alone or as part of
cellular debris or apoptotic bodies, which is caused by increased
rates of tumor cell death (Kepp et al., 2009), will promote thec.
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tive or phospholipid-specific autoantibodies. Subsequently, the
concomitant induction of IL-12 production resulting from FcRn
ligation by IgG IC can be expected to further amplify local
FcRn-dependent antitumor immune responses because IL-12
is a potent inducer of humoral immunity (Metzger, 2010). A key
physiological role for FcRn within DCs therefore appears to be
the integration of humoral and cellular adaptive immune re-
sponses capable of targeting mucosal malignancies and, un-
doubtedly, a host of intracellular microbial infections.
Several intriguing aspects of FcRn biology emerge from our
work. The first of these is that FcRn-dependent immune regula-
tion is operative under homeostatic conditions and is critical for
establishing baseline colonic CD8+ T cell activation and function.
We predict that such homeostatic responses are largely directed
at microbial antigens given that IgG with antibacterial specific-
ities are abundantly present in the intestine (Macpherson et al.,
1996) and that the pathways described here may also play a crit-
ical role in immune surveillance against acute and chronic micro-
bial infections (Yoshida et al., 2006). Second, our work highlights
the differential role played by FcRn in different body compart-
ments. Whereas FcRn is critical for maintaining IgG persistence
within the circulatory system (Roopenian et al., 2003), our obser-
vations indicate that within tissues, FcRn is predominantly
involved in the regulation of local immune responses. In addition
to the inadequate immune activation seen in the intestines of
Fcgrt/ mice, this idea is supported by our findings that
Fcgrt/mice were only minimally deficient in tissue IgG quanti-
ties where equal amounts of IgG producing cells were able to
compensate for the lack of FcRn-mediated IgG protection.
Finally, we have demonstrated the feasibility and effectiveness
of targeting FcRn-mediated anticancer immunosurveillance
pathways by using a single defined tumor antigen in complex
with native IgG or IgG engineered for enhanced FcRn binding.
In addition to enabling antigen-specific CD8+ T cell-mediated
immunity after tumor onset, such therapies also have the poten-
tial to promote tumor immunosurveillance in healthy high-risk
individuals by enhancing the baseline cytotoxic potential of the
intestine toward common tumor antigens. Although a large
body of knowledge exists pertaining to the dynamics of FcRn-
IgG interaction (Vaughn et al., 1997) and the ability to engineer
IgG with increased affinity for FcRn is currently available
(Mi et al., 2008; Zalevsky et al., 2010), targeting of FcRn has
yet to be exploited by current DCs-based vaccination strategies
(Tacken et al., 2007) despite the growing interest in DCs anti-
cancer vaccines (Palucka and Banchereau, 2013).
The pleiotropic nature of FcRn and its wide-reaching influence
on normal physiology remain poorly understood. Whereas the
main function of FcRn systemically is the protection of mono-
meric IgG from catabolism, a major role in tissues, particularly
mucosal tissues replete with IgG, appears to be one of immuno-
logical activation upon ligation by multimeric IgG IC. To this
effect, FcRn participates in the organization not only of an anti-
gen presentation cascade but also of a signaling cascade that
is associated with innate effector immune function. As shown
here, a major consequence of this role for FcRn is the efficient in-
duction of antitumor immunity. These studies show that FcRn
functions in antitumor immunosurveillance through the induction
(via IL-12) and instruction (via cross-presentation) of CD8+ImmT cells. Developing a greater understanding of the nuances of
FcRn-modulated immune activation, particularly at the tissue
level where FcRn in DCs promotes the immunogenic catabolism
of IgG-complexed antigens, holds considerable promise for the
development of new therapies against mucosal diseases.
EXPERIMENTAL PROCEDURES
Mice and Tumor Models
Fcgrt/mice (Roopenian et al., 2003), deficient in FcRn, on a C57BL/6 back-
groundwere originally purchased from The Jackson Laboratory. FcgrtFl/Flmice
were a kind gift of Dr. E. Sally Ward (University of Texas Southwestern Medical
Center) (Montoyo et al., 2009). hFCGRT-hB2M-mFcgrt/ mice have been
described previously (Yoshida et al., 2004). Additional mouse strains are
described in Supplemental Experimental Procedures. All procedures were
approved by the Harvard Medical Area Standing Committee on Animals.
AOM, AOM/DSS, ApcMin/+, and lung metastasis tumor models were per-
formed with previously described protocols (Leibundgut-Landmann et al.,
2008; Meunier et al., 2010;Wirtz et al., 2007) and are described fully in the Sup-
plemental Experimental Procedures.
Microbiota Analysis
Analysis of the microbiota was conducted as outlined in Supplemental Exper-
imental Procedures with previously published methods (Uronis et al., 2011).
Human DCs and Tissue Experiments
Human leukopackswere obtained from the Kraft Family Blood Donor Center of
the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
hMoDCs were derived as previously described (Zeissig et al., 2010) for
5 days in 1,000 U/ml hGM-CSF and 500 U/ml hIL-4. During the final 24 hr of
culture, 100 U/ml IFN-gwas added. IgG and IHH-IgG stimulations were carried
out as described above. One set of human CRC tissue microarrays containing
50 samples of matched tumor and adjacent normal tissue from the same do-
nors were obtained from BioMax USA. A second TMA containing multiple
punches from each of 220 patients and for which survival data was available
has previously been described (Karamitopoulou et al., 2011). Tissue was
stained with the EnVision G2 Doublestain System, Rabbit/Mouse (DAB+/
Permanent Red) Kit from Dako following heat-induced epitope retrieval in
10 mM citrate, 1 mM EDTA, 0.05% Tween (pH 6.0). Primary antibodies were
anti-hFCGRT (HPA012122, Sigma Aldrich), anti-hCD11c (Novocastra), and
anti-hCD8 (Dako), all of which were used at 1/50. Experiments were performed
under Brigham and Women’s Hospital Review Board approval.
Biochemical Methods
Flow cytometry, RNA analysis, IgG quantification, ChIP, immunoblotting,
ELISpot, and in vitro coculture experimentswereconducted asoutline inSupple-
mentalExperimentalProceduresandaspreviouslydescribed (Bakeretal., 2011).
Statistical Analyses
All data are expressed as mean ± SEM. Unless otherwise specified, data was
analyzed with two-tailed unpaired Student’s t tests. Significance of results
across independent experiments was assessed by pairwise Student’s t test.
As indicated where relevant, non-normally distributed data was assessed
with Mann-Whitney test and survival for mouse experiments was evaluated
with Logrank test or chi-square test. The human survival analysis was per-
formed with the Kaplan-Meier method, and the two curves were compared
with the log rank test. Subsequently, FcRn+CD11c+ status was entered into
uni- and multivariate Cox regression analysis. Hazard ratios (HR) and 95%
confidence intervals (CI) were used to determine the prognostic effect of
FcRn+CD11c+ cell numbers on survival time. All analyses were carried out
with GraphPad Prism software (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2013.11.003.unity 39, 1095–1107, December 12, 2013 ª2013 Elsevier Inc. 1105
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